GlassScriptPhysician profile
Collin M Blattner
NPI 1669868493
$408,940.09
in general payments reported to CMS, 2019-2025
30 companies · $127K in 2025
The $127K reported for 2025 was more than what 98% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,646 · 2020: $793 · 2021: $1,381 · 2022: $14K · 2023: $120K · 2024: $143K · 2025: $127K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $222K · Consulting Fee: $90K · Travel and Lodging: $59K · Food and Beverage: $19K · Education: $254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $221,754.50 |
| Consulting Fee | $90,345.00 |
| Travel and Lodging | $58,855.15 |
| Food and Beverage | $18,797.44 |
| Education | $253.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $147,015.02 | 2022-2025 | Otezla, Otezla, Amjevita |
| Pfizer INC. | $94,208.43 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $46,781.62 | 2019-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $46,646.95 | 2019-2025 | Cosentyx |
| E.R. Squibb & Sons, L.L.C. | $24,565.54 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $18,577.03 | 2019-2025 | Odomzo, Winlevi, Ilumya |
| Arcutis Biotherapeutics, INC. | $12,009.59 | 2023-2024 | Zoryve |
| Takeda Pharmaceuticals U.S.A., INC. | $4,026.93 | 2025 | |
| Genzyme Corporation | $3,529.38 | 2019-2025 | |
| Dermavant Sciences, INC. | $3,291.01 | 2022-2023 | Vtama |
| Abbvie INC. | $3,004.37 | 2019-2025 | Skyrizi, Rinvoq |
| Ucb, INC. | $1,460.51 | 2022-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $927.36 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $875.94 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Leo Pharma INC. | $808.63 | 2019-2025 | Adbry, Anzupgo, Spevigo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $259.43 | 2019-2024 | Siliq |
| Incyte Corporation | $203.66 | 2022-2024 | Opzelura |
| Merz North America, INC. | $138.92 | 2023 | Xeomin |
| Galderma Laboratories, L.P. | $119.76 | 2019-2024 | Aklief |
| Regeneron Pharmaceuticals, INC. | $102.08 | 2024-2025 | Dupixent |
| Almirall LLC | $91.07 | 2025 | Klisyri |
| Biofrontera INC. | $78.64 | 2021-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Organogenesis INC. | $74.65 | 2023-2024 | Puraply |
| Celgene Corporation | $44.75 | 2019 | |
| Medtronic, INC. | $19.68 | 2022 | |
| Smith+Nephew, INC. | $17.44 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $16.29 | 2019 | |
| Csl Behring | $15.97 | 2019 | |
| Strata Skin Sciences, INC. | $14.72 | 2023 | Xtrac |
| Pharming Healthcare, INC. | $14.72 | 2024 | Ruconest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Collin Blattner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.